RSS

Issue 17.5

In this instalment, R&D software provider, IDBS, lists the four considerations that are important when implementing integrated solutions. more

Opinion

Allison Gilpin, business unit manager, global serialisation and Ray Hook, manager global serialisation services, PCI Pharma Services, discuss the impact of serialisation requirements on packaging operations. more

, Opinion

Are you preparing for serialisation? Carlos Machado, SEA Vision US, explores some of the challenges and opportunities companies are facing when preparing for serialisation and outlines some steps to success for those that are yet to make a start. more

Opinion

With serialisation efforts in full swing connecting the dots across the full supply chain is becoming important. Here, Christophe Devins and Chuck Sailer, Adents, explain why Level 4 serialisation is uniquely positioned for data sharing. more

, Opinion

‘Advanced simplicity’ will drive growth for inhalers in emerging markets, Peter Schmelzer, CEO of H&T Presspart tells us more. more

Opinion

Jason Teckoe, technical director, Colorcon EMEA, discusses the important considerations when coating oral solid dosage forms. more

Opinion

Bruno Speder, SGS Life Sciences, gives an overview of new EU regulation 536/2014, introduced to provide a single European submission and approval procedure for clinical trials, and discusses the effects it may have on early phase clinical trials more

Opinion

A recent partnership to address the challenge of monitoring adherence in ophthalmic clinical trials was formed between Aptar Pharma and Kali Care. Here, Sina Fateh and Sai Shankar discuss this alliance further. more

, Opinion

Jennifer Goldsmith, senior vice president of Veeva Vault, examines why industry collaboration holds the key to faster clinical trials more

Opinion

In this article, Ben van der Schaaf, principal at Arthur D. Little, gives a five-step guide to explore possible funding partnerships for lower-priority drug trials — a new model for big pharma. more

Opinion

Speed to market is a significant concern in tablet manufacturing, however, moving too quickly may cause problems. Here, Dr Charles Kettler and Robert Sedlock reveal anticipatory experiments to help make the transition from R&D to full scale smooth. more

, Opinion

Dr Rajendra Wable, subject matter expert-medical writing and regulatory affairs at ‎Sciformix Corporation, discusses how marketing authorisation applications across Europe, Australia and other countries can be supported with non-clinical overviews more

Opinion

Dr Prashanth BSB, head of safety and medical writing for ELC Group, talks to EPM about the ramifications Brexit may have on the pharmacovigilance landscape. more

Opinion

Dr Marisa Miraldo, associate professor in Health Economics at Imperial College Business School, London, discusses ways to accelerate innovation in healthcare for the benefit of patients, healthcare providers and industry. more

Opinion

Focusing on the keys to success for contract drug manufacturers, Arnaud Sergent, Serge Hovsepian, Nohmie Ben Rekassa and Ben Faircloth from L.E.K. Consulting detail the differentiation strategies that have proven themselves in the marketplace more

, , , Opinion

R&D efficiency has been in decline for many years, but now with bodies, like the FDA, aiming to accelerate approval times and a critical need for new therapies to combat antibiotic resistant strains of bacteria will we see the tide turn? more

Opinion